174 related articles for article (PubMed ID: 37661910)
21. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.
Vanderstraeten A; Luyten C; Verbist G; Tuyaerts S; Amant F
Cancer Immunol Immunother; 2014 Jun; 63(6):545-57. PubMed ID: 24658839
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
[TBL] [Abstract][Full Text] [Related]
23. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site.
Junior JNA; Preto DD'; Lazarini MEZN; de Lima MA; Bonatelli M; Berardinelli GN; da Silva VD; Pinheiro C; Reis RM; Cárcano FM
Int J Clin Oncol; 2024 Jun; 29(6):726-734. PubMed ID: 38528294
[TBL] [Abstract][Full Text] [Related]
25. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
[TBL] [Abstract][Full Text] [Related]
26. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
Xie L; Liang X; Xu J; Sun X; Liu K; Sun K; Li Y; Tang X; Li X; Zhan X; Niu X; Guo W
BMC Cancer; 2023 Sep; 23(1):868. PubMed ID: 37715133
[TBL] [Abstract][Full Text] [Related]
27. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial.
Tamura K; Hasegawa K; Katsumata N; Matsumoto K; Mukai H; Takahashi S; Nomura H; Minami H
Cancer Sci; 2019 Sep; 110(9):2894-2904. PubMed ID: 31348579
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
30. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
31. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
32. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
[TBL] [Abstract][Full Text] [Related]
33. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
[TBL] [Abstract][Full Text] [Related]
34. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
[TBL] [Abstract][Full Text] [Related]
36. Prognostic relevance of programmed death-ligand 1 expression and microsatellite status in small bowel adenocarcinoma.
Klose J; Lasitschka F; Horsch C; Strowitzki MJ; Bruckner T; Volz C; Schmidt T; Schneider M
Scand J Gastroenterol; 2020 Mar; 55(3):321-329. PubMed ID: 32191146
[No Abstract] [Full Text] [Related]
37. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression in sarcomas: An immunohistochemical study and review of the literature.
Cunningham CR; Dodd L; Esebua M; Layfield LJ
Ann Diagn Pathol; 2021 Dec; 55():151823. PubMed ID: 34656856
[TBL] [Abstract][Full Text] [Related]
39. Emerging Targeted and Immune-Based Therapies in Sarcoma.
Pollack SM; Ingham M; Spraker MB; Schwartz GK
J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
[TBL] [Abstract][Full Text] [Related]
40. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer.
Yang Z; Wu G; Zhang X; Gao J; Meng C; Liu Y; Wei Q; Sun L; Wei P; Bai Z; Yao H; Zhang Z
Front Immunol; 2022; 13():1001444. PubMed ID: 36159842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
